Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Zhao, Z., Wolkenberg, S.E., Lu, M., Munshi, V., Moyer, G., Feng, M., Carella, A.V., Ecto, L.T., Gabryelski, L.J., Lai, M.T., Prasad, S.G., Yan, Y., McGaughey, G.B., Miller, M.D., Lindsley, C.W., Hartman, G.D., Vacca, J.P., Williams, T.M.(2008) Bioorg Med Chem Lett 18: 554-559
- PubMed: 18083561
- DOI: https://doi.org/10.1016/j.bmcl.2007.11.085
- Primary Citation of Related Structures:
2RF2 - PubMed Abstract:
This Letter describes the design, synthesis, and biological evaluation of novel 3-indole sulfonamides as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) with balanced profiles against common HIV RT mutants K103N and Y181C.
Organizational Affiliation:
Department of Medicinal Chemistry, Merck & Co., Inc., PO Box 4, West Point, PA 19486, USA. zhijian_zhao@merck.com